4Fadl Elmula I, Gorunova L, Mandahl N, et al. Karyotypic characterization of urinary bladder transitional cell carcinomas. Gene Chromosome Canc,2000;29(3) :256-265.
5Richter J, Jiang F, Gorog JP, et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res,1997;57(14) :2860-2864.
6Sokolova IA, Hailing KC, Jenkins RB, etal. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn,2000;2(3) :116 123.
7Sarosdy MF, Schellhammer P, Bokinsky G, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol, 2002; 168 (5) :1950-1954.
8Sarosdy MF, Kahn PR, Ziffer MD, et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol,2006 , 176( 1 ) :44-47.
9Eble JN, Sauter G, Epstein JI. Tumours of the urinary system. In= Eble JN, Sauter G, Epstein JI. Pathology and genetics of tumors of the urinary system and male genital organs. 3rd ed. Lyon: IARC Press,2004:93-113.
10Onishi T, Ichikawa T, Igarashi T. Study on the diagnosis of urothelial cancer using multi colour fluorescence in situ hybridization (FISH) comparative analysis between FISH and cytology. Hinyokika Kiyo,2008;54(4) :253 -256.
3Ecke TH. Focus on urinary bladder cancer markers: a review[J]. Minerva Urol Nefrol, 2008, 60(4) : 237-246.
4Jemal A, Siegel R, Xu J, et al. Cancer statistics,2010[J]. CA Cancer J Clin, 2010, 60(5) : 277-300.
5Soloway MS, Briggman V, Carpinito GA, et al. Use of a new mark- er, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment[J]. J Urol, 1996, 156(21 Pt) : 363-367.
6Ann JS, Kim HS, Chang SG, et al. The clinical usefulness of nu- clear matrix protein-22 in patients with atypical arine cytology [ J]. Korean J Urol, 2011, 52(9) : 603-605.
7Arora VK, Sarungbam J, Bhatia A, et al. Usefulness of NMP22 as an adjunct to a typical urine cytology and low-grade urothelial carci- noma[J]. Diagn Cytopathol, 2010, 38(11) : 788-790.
8Keesee SK, Briggman JV, Thill G, et al. Utilization of nuclear ma- trix proteins for cancer diagnosis [ J ]. Crit RevEukayotic Gene Expr, 1996, 6(2/3): 189-214.
9Sharmat S, Zippe CD, Pandrangi I, et al. Exclusion criteria en- hance the specificity and positive predictive value of NMP22 and BTAstat[J]. JUrol, 1999, 162(1): 53-57.
10Xu AD, Ng CS, Kamat A, et al. Significance of upper urinary tract urothelial thickening and filling defect seen on MDCT urography in patients with a history of urothelial neoplasms [J]. Am J Roentge.ol, 2010, 195(4):959-965.
